Comparative Pharmacology
Head-to-head clinical analysis: CHRONULAC versus GO EVAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHRONULAC versus GO EVAC.
CHRONULAC vs GO-EVAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic pH, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.
Promotes gastrointestinal motility by acting as a stimulant laxative, likely through direct irritation of the colonic mucosa and possibly via local effects on enteric neurons.
10-30 mL orally once daily to twice daily; for acute constipation, 20-30 mL initially; for hepatic encephalopathy, 30-60 mL every 1-2 hours to achieve 2-3 soft stools daily.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life approximately 1.5-2.5 hours in adults with normal renal function; may be prolonged to 4-8 hours in patients with renal impairment.
4.5-6 hours in healthy volunteers; prolonged to 10-14 hours in elderly patients and those with moderate renal impairment (CrCl 30-50 mL/min).
Primarily renal (as unchanged drug and metabolites): ~40-50% of dose excreted in urine within 24 hours; biliary/fecal elimination accounts for the remainder, with approximately 2-5% recovered in feces as parent compound.
Primarily renal; approximately 60% eliminated unchanged in urine within 24 hours, with 20% as metabolites. Biliary/fecal excretion accounts for 15-20%, and the remainder is metabolized via glucuronidation.
Category C
Category C
Osmotic Laxative
Osmotic Laxative